Literature DB >> 2945811

Comparison of pharmacokinetics and bactericidal activity of teicoplanin and vancomycin.

H Lagast, P Dodion, J Klastersky.   

Abstract

Teicoplanin (0.2 g) or vancomycin (1 g) were infused over 3 and 50 min respectively to six male volunteers in a cross-over study. Each drug was administered twice at a 14 h interval. The pharmacokinetics of both drugs were accurately described using a two-compartment model. Vancomycin had a shorter half-life (5.8 +/- 1.8 h) compared to teicoplainin (33.2 +/- 5.1 h; P less than 0.001). One hour serum was tested for serum bactericidal activity against ten strains each of Staphylococcus aureus (median serum bactericidal activity 1:16 for teicoplanin; 1:32 for vancomycin), Staph. epidermidis (1:32 for teicoplanin and for vancomycin) and Streptococcus faecalis (1:2 for both drugs). Serum killing rate studies showed a slower rate of killing of Staph. aureus with teicoplanin (less than 1 log10 cfu/ml over 6 h) than with vancomycin (4 log10 cfu/ml over 6 h).

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2945811     DOI: 10.1093/jac/18.4.513

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  11 in total

1.  Antistaphylococcal activities of teicoplanin and vancomycin in vitro and in an experimental infection.

Authors:  W E Peetermans; J J Hoogeterp; A M Hazekamp-van Dokkum; P van den Broek; H Mattie
Journal:  Antimicrob Agents Chemother       Date:  1990-10       Impact factor: 5.191

Review 2.  Safety considerations in the use of drug combinations during general anaesthesia.

Authors:  E S Ransom; R A Mueller
Journal:  Drug Saf       Date:  1997-02       Impact factor: 5.606

3.  Vancomycin-induced histamine release and "red man syndrome": comparison of 1- and 2-hour infusions.

Authors:  D P Healy; J V Sahai; S H Fuller; R E Polk
Journal:  Antimicrob Agents Chemother       Date:  1990-04       Impact factor: 5.191

4.  Comparison of vancomycin- and teicoplanin-induced histamine release and "red man syndrome".

Authors:  J Sahai; D P Healy; M J Shelton; J S Miller; S J Ruberg; R Polk
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

5.  Teicoplanin pharmacokinetics in patients undergoing continuous ambulatory peritoneal dialysis after intravenous and intraperitoneal dosing.

Authors:  D R Guay; W M Awni; C E Halstenson; M T Kenny; W F Keane; G R Matzke
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

Review 6.  Clinical pharmacokinetics of teicoplanin.

Authors:  M Rowland
Journal:  Clin Pharmacokinet       Date:  1990-03       Impact factor: 6.447

7.  In vivo activities of ceftriaxone and vancomycin against Borrelia spp. in the mouse brain and other sites.

Authors:  R J Kazragis; L L Dever; J H Jorgensen; A G Barbour
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

8.  Pharmacokinetics of teicoplanin in renal failure.

Authors:  C Falcoz; N Ferry; N Pozet; G Cuisinaud; P Y Zech; J Sassard
Journal:  Antimicrob Agents Chemother       Date:  1987-08       Impact factor: 5.191

9.  In vitro studies of pharmacodynamic properties of vancomycin against Staphylococcus aureus and Staphylococcus epidermidis.

Authors:  E Löwdin; I Odenholt; O Cars
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

10.  Comparative effect of protein binding on the killing activities of teicoplanin and vancomycin.

Authors:  E M Bailey; M J Rybak; G W Kaatz
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.